Summary.-A new hypoxic cell radiosensitizer, Ro 03-8799, has been administered i.v. to 2 normal and 6 patient volunteers. Generally in non-necrotic tumours the concentrations obtained were 3 times greater than in plasma sampled at the same time. These observations added to the reports concerning toxicology in monkeys and rats and radiosensitizing efficiency in the laboratory, suggest that Ro 03-8799 may prove to be a much more effective sensitizer than misonidazole in man.
THE NEUROTOXICITY of misonidazole (MISO) has limited the total dose of this radiosensitizing drug which may be given to patients. A considerable effort is currently being made to develop new drugs which will show greater activity and/or reduced toxicity so that there can be greater sensitization of hypoxic cells in human tumours.
Nitroimidazoles which have a lower lipophilicity than MISO are being investigated because they have the promise of a shorter half-life in plasma and a reduced uptake in the central nervous system compared with MISO. Unfortunately, the first of these compounds to be tested clinically, desmethylmisonidazole, has generated an incidence of peripheral neuropathy similar to that of MISO (Dische et al., 1981a) .
A further area of research is in the synthesis of lipophilic nitroimidazoles containing a basic side chain. These might be expected to show both an increased penetration into tissues, including tumours and a shortened half-life (Smithen et al., 1980) . There is the further possibility that such compounds may be concentrated in areas of low pH such as may commonly be found in tumours (Wardman, 1982) .
The basic compound, Ro 03-8799, was one of a series synthesized by Smithen et at. (1980) In vitro studies showed a 10-fold advantage over MISO as a radiosensitizer but although improved sensitization has been shown in vivo the factor has been reduced to < 4 (Smithen et al., 1980) . This compound must be given i.v. since after oral administration it is absorbed slowly and then extensively metabolized to the much less active N-oxide form. After i.v. administration to mice, rats and monkeys, there is a rapid clearance and a high distribution volume which indicates concentration within tissues, in contrast to MISO which has a distribution volume similar to that of the total body fluid (Schwade et al., 1979 Quantities of Ro 03-8799 are reported as free "base" and not as the HCI salt, the form in which the drug is supplied. The types of tumour and areas sampled are shown in Table I .
RESULTS
No effect due to the drug was observed after any one of the 10 administrations. Subsequent serial haematological and biochemical tests, including those of liver function, failed to show any abnormality.
The drug was rapidly cleared from the plasma after the i.v. infusion. A mean 2-2 life of 6-1 + 0-7 min (s.e.) was calculated for the distribution phase and the elimination 2-life was 5-2 + 0-6 h giving values in keeping with observations previously made in animals. A study of 14C levels showed that -70% of the given dose was excreted in the urine within 48 h part as unchanged Ro 03-8799 but the majority in altered form. Low levels of activity were detected in the faeces and none in the expired air. Red cell levels were 1-5-2-0 x greater than those in the plasma demonstrating the concentration in cells. The pharmacokinetic data will be fully detailed by Malcolm et al. (in preparation Table II would be lower than the levels of Ro 03-8799 present in the tumours in vivo. MISO is the radiosensitizing compound which has been most extensively studied in the laboratory and in the clinic. When 1 g of MISO is given to a patient of average size, the concentration in the plasma at the time usually chosen for radiotherapy, 3-4 h after treatment, will be -24 tig/ml.
With MISO the tumour concentration is, on average, 80% of the plasma concentration, and so we can expect a level of 19 ,ig/g (Dische et al., 1981b) .
From our observations with Ro 03-8799, 1 g of the pure base when administered will give a plasma concentration of -10 Htg/ml at 30 min, the time when it would probably be best to give radiotherapy. From the observations we have made, we can suggest that the concentration in tumour at that time will be 30 ,tg/g. In addition to the greater tumour concentration, Williams et al. (1982) concluded from their work with tumours in mice that, when tumour concentrations of Ro 03-8799 and misonidazole are compared on a molar basis, then Ro 03-8799 is 3 x as effective as a sensitizer.
In the development of nitroimidazoles as radiosensitizing drugs a great effort has been made to find an animal system which will predict the toxicity to be observed in man. So far, no completely satisfactory model has been found. The most reliable guidance has been obtained from toxicological studies where there was daily administration to animals over some weeks; the most valuable observations have been made in primates. With Ro 03-8799, a 28-day i.v. toxicity study has been undertaken in rats and cynomolgus monkeys by Roche Products Ltd (Eichler & Jackson, personal communication, 1982) . In the monkeys, dose levels of the hydrochloride salt were 50, 120 or 300 mg/kg/day for the first 10 days. At this time, one animal in the high dose group died and microscopic examination showed acute hepatic damage: the dosage was then reduced to 33, 80 and 200 mg/kg for the remainder of the study. Some of the animals given 300 mg/kg/day had shown some hepatotoxicity at the end of 10 days, as indicated by the results of function tests, but these values, when repeated after lowering the dose to 200 mg/kg/day, showed a return to control levels. There was no morphological evidence of hepatic damage at the termination of the study. A toxicological study using similar doses of Ro 03-8799 has been performed in rats without obvious hepatotoxicity. In the monkeys, there was no adverse effect noted on spermatogenesis but some salivation was noted in those receiving the middle and high dose levels. Muscle tremor and vomiting were observed occasionally in the highest dose group of monkeys while some locomotor disturbances lasting a few minutes to several hours were seen in the rats which were also in the highest dose group.
These observations compare favourably with those found with MISO when this drug was also given by the i.v. route. With a dose regime of 100 mg/kg/day severe neurotoxicity was encountered (Eichler & Jackson, personal communication, 1982) .
The toxicological studies performed so far would suggest that the tolerance of man to Ro 03-8799 may prove to be twice that of MISO.
Improved tolerance, higher concentration in tumour and greater radiosensitizing efficiency may prove Ro 03-8799 to be a considerable improvement as a radiosensitizer when compared with misonidazole. Only a full-scale study will determine, however, whether this promise will be achieved. The evidence is certainly encouraging and a more extensive administration of the drug to man is being undertaken.
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